Stem definition | Drug id | CAS RN |
---|---|---|
antihyperlipidaemics, acyl CoA: cholesterol acyltransferase (ACAT) inhibitors | 1125 | 163222-33-1 |
Dose | Unit | Route |
---|---|---|
10 | mg | O |
Property | Value | Reference |
---|---|---|
BDDCS (Biopharmaceutical Drug Disposition Classification System) | 2 | Benet LZ, Broccatelli F, Oprea TI |
EoM (Fraction excreted unchanged in urine) | 2 % | Benet LZ, Broccatelli F, Oprea TI |
MRTD (Maximum Recommended Therapeutic Daily Dose) | 0.35 µM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
BA (Bioavailability) | 50 % | Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H |
Date | Agency | Company | Orphan |
---|---|---|---|
Oct. 25, 2002 | FDA | MSD INTL GMBH | |
April 18, 2007 | PMDA | Schering-Plough K.K |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Myalgia | 794.77 | 10.38 | 881 | 62294 | 132610 | 53153281 |
Rhabdomyolysis | 664.82 | 10.38 | 491 | 62684 | 43432 | 53242459 |
Blood creatine phosphokinase increased | 309.33 | 10.38 | 264 | 62911 | 28721 | 53257170 |
Low density lipoprotein increased | 217.74 | 10.38 | 118 | 63057 | 6048 | 53279843 |
Contraindicated product administered | 131.87 | 10.38 | 7 | 63168 | 135622 | 53150269 |
Muscle spasms | 123.87 | 10.38 | 396 | 62779 | 134399 | 53151492 |
Maternal exposure during pregnancy | 117.90 | 10.38 | 21 | 63154 | 155618 | 53130273 |
Myopathy | 117.32 | 10.38 | 95 | 63080 | 9597 | 53276294 |
Pemphigus | 109.16 | 10.38 | 3 | 63172 | 104028 | 53181863 |
Rheumatoid arthritis | 107.15 | 10.38 | 129 | 63046 | 314402 | 52971489 |
Drug ineffective | 105.54 | 10.38 | 555 | 62620 | 816690 | 52469201 |
Coronary artery disease | 101.75 | 10.38 | 159 | 63016 | 33278 | 53252613 |
Synovitis | 100.55 | 10.38 | 7 | 63168 | 107886 | 53178005 |
Muscular weakness | 97.61 | 10.38 | 302 | 62873 | 100690 | 53185201 |
Myocardial infarction | 95.93 | 10.38 | 297 | 62878 | 99057 | 53186834 |
Angina pectoris | 93.60 | 10.38 | 141 | 63034 | 28584 | 53257307 |
Pancreatitis acute | 93.51 | 10.38 | 134 | 63041 | 25975 | 53259916 |
Liver function test abnormal | 87.75 | 10.38 | 183 | 62992 | 47888 | 53238003 |
Toxicity to various agents | 81.37 | 10.38 | 84 | 63091 | 219514 | 53066377 |
Infusion related reaction | 80.64 | 10.38 | 42 | 63133 | 155915 | 53129976 |
Acute kidney injury | 79.14 | 10.38 | 543 | 62632 | 253325 | 53032566 |
Pain in extremity | 78.08 | 10.38 | 591 | 62584 | 284459 | 53001432 |
Death | 69.17 | 10.38 | 206 | 62969 | 357026 | 52928865 |
Off label use | 68.61 | 10.38 | 307 | 62868 | 471905 | 52813986 |
Pancreatitis | 65.56 | 10.38 | 159 | 63016 | 45983 | 53239908 |
Wound | 63.82 | 10.38 | 15 | 63160 | 91542 | 53194349 |
Exposure during pregnancy | 62.53 | 10.38 | 35 | 63140 | 124825 | 53161066 |
Coronary artery occlusion | 62.13 | 10.38 | 62 | 63113 | 8225 | 53277666 |
Treatment failure | 61.46 | 10.38 | 38 | 63137 | 128365 | 53157526 |
Completed suicide | 60.67 | 10.38 | 45 | 63130 | 138156 | 53147735 |
Hyper IgE syndrome | 58.05 | 10.38 | 21 | 63154 | 400 | 53285491 |
Product use issue | 58.05 | 10.38 | 48 | 63127 | 139536 | 53146355 |
Blood cholesterol increased | 57.36 | 10.38 | 165 | 63010 | 52824 | 53233067 |
Hyperlipidaemia | 56.87 | 10.38 | 91 | 63084 | 19424 | 53266467 |
Acute coronary syndrome | 55.35 | 10.38 | 65 | 63110 | 10359 | 53275532 |
Pericarditis | 55.05 | 10.38 | 6 | 63169 | 64400 | 53221491 |
Glossodynia | 51.84 | 10.38 | 27 | 63148 | 100264 | 53185627 |
Aspartate aminotransferase increased | 51.03 | 10.38 | 216 | 62959 | 83813 | 53202078 |
High density lipoprotein decreased | 50.19 | 10.38 | 30 | 63145 | 1855 | 53284036 |
Systemic lupus erythematosus | 49.87 | 10.38 | 45 | 63130 | 125369 | 53160522 |
Alanine aminotransferase increased | 49.14 | 10.38 | 233 | 62942 | 94862 | 53191029 |
Arterial stenosis | 48.65 | 10.38 | 21 | 63154 | 647 | 53285244 |
Blood glucose increased | 47.86 | 10.38 | 200 | 62975 | 77161 | 53208730 |
Blood triglycerides increased | 46.23 | 10.38 | 65 | 63110 | 12376 | 53273515 |
Vascular stent stenosis | 45.61 | 10.38 | 19 | 63156 | 535 | 53285356 |
Intentional overdose | 44.92 | 10.38 | 12 | 63163 | 67193 | 53218698 |
Drug abuse | 43.23 | 10.38 | 12 | 63163 | 65514 | 53220377 |
Therapeutic product effect decreased | 42.20 | 10.38 | 52 | 63123 | 125603 | 53160288 |
Flatulence | 42.01 | 10.38 | 106 | 63069 | 31411 | 53254480 |
Dyslipidaemia | 41.40 | 10.38 | 44 | 63131 | 6283 | 53279608 |
Joint swelling | 40.01 | 10.38 | 143 | 63032 | 234495 | 53051396 |
Carotid arteriosclerosis | 39.66 | 10.38 | 21 | 63154 | 1026 | 53284865 |
Polymyositis | 39.15 | 10.38 | 25 | 63150 | 1739 | 53284152 |
Dizziness | 39.00 | 10.38 | 638 | 62537 | 371621 | 52914270 |
Infection | 38.79 | 10.38 | 92 | 63083 | 172113 | 53113778 |
Immune-mediated myositis | 38.58 | 10.38 | 21 | 63154 | 1085 | 53284806 |
Cardiac failure congestive | 37.99 | 10.38 | 213 | 62962 | 92544 | 53193347 |
Febrile neutropenia | 36.76 | 10.38 | 42 | 63133 | 104894 | 53180997 |
Arterial occlusive disease | 36.43 | 10.38 | 37 | 63138 | 5012 | 53280879 |
Restrictive pulmonary disease | 34.36 | 10.38 | 22 | 63153 | 1537 | 53284354 |
Coombs positive haemolytic anaemia | 34.23 | 10.38 | 14 | 63161 | 376 | 53285515 |
Sensorimotor disorder | 34.13 | 10.38 | 15 | 63160 | 483 | 53285408 |
Myositis | 34.05 | 10.38 | 46 | 63129 | 8437 | 53277454 |
Angina unstable | 33.86 | 10.38 | 43 | 63132 | 7425 | 53278466 |
Pyrexia | 33.79 | 10.38 | 310 | 62865 | 402883 | 52883008 |
Muscle rupture | 33.60 | 10.38 | 25 | 63150 | 2229 | 53283662 |
Antinuclear antibody negative | 33.20 | 10.38 | 12 | 63163 | 228 | 53285663 |
Muscle disorder | 32.01 | 10.38 | 33 | 63142 | 4548 | 53281343 |
Crush syndrome | 31.74 | 10.38 | 10 | 63165 | 122 | 53285769 |
Asthenia | 31.67 | 10.38 | 577 | 62598 | 343013 | 52942878 |
Swelling | 31.56 | 10.38 | 118 | 63057 | 190987 | 53094904 |
Myopathy toxic | 30.16 | 10.38 | 13 | 63162 | 399 | 53285492 |
Lipids increased | 29.83 | 10.38 | 18 | 63157 | 1132 | 53284759 |
Cerebrovascular accident | 29.22 | 10.38 | 219 | 62956 | 104955 | 53180936 |
Chest pain | 28.77 | 10.38 | 348 | 62827 | 189837 | 53096054 |
Disease progression | 28.48 | 10.38 | 48 | 63127 | 101872 | 53184019 |
Neutropenia | 28.48 | 10.38 | 95 | 63080 | 159090 | 53126801 |
Duodenal ulcer perforation | 28.30 | 10.38 | 4 | 63171 | 35179 | 53250712 |
Hyperkalaemia | 28.06 | 10.38 | 133 | 63042 | 54123 | 53231768 |
Palpitations | 27.81 | 10.38 | 212 | 62963 | 102136 | 53183755 |
Herpes simplex reactivation | 27.79 | 10.38 | 12 | 63163 | 370 | 53285521 |
Hypoglycaemia | 27.20 | 10.38 | 140 | 63035 | 58873 | 53227018 |
Inhibitory drug interaction | 26.77 | 10.38 | 22 | 63153 | 2268 | 53283623 |
Body tinea | 26.60 | 10.38 | 17 | 63158 | 1184 | 53284707 |
Gangrene | 25.21 | 10.38 | 30 | 63145 | 4847 | 53281044 |
Aortic stenosis | 25.14 | 10.38 | 29 | 63146 | 4534 | 53281357 |
Transient ischaemic attack | 24.99 | 10.38 | 96 | 63079 | 35629 | 53250262 |
Polycystic ovaries | 24.81 | 10.38 | 21 | 63154 | 2255 | 53283636 |
Microscopic polyangiitis | 24.76 | 10.38 | 9 | 63166 | 174 | 53285717 |
Glucose tolerance impaired | 24.70 | 10.38 | 31 | 63144 | 5289 | 53280602 |
Coma acidotic | 23.52 | 10.38 | 8 | 63167 | 126 | 53285765 |
Lower respiratory tract infection | 23.48 | 10.38 | 45 | 63130 | 90936 | 53194955 |
Arthropathy | 22.91 | 10.38 | 88 | 63087 | 141365 | 53144526 |
Gait disturbance | 22.87 | 10.38 | 288 | 62887 | 158554 | 53127337 |
Device expulsion | 22.60 | 10.38 | 4 | 63171 | 29809 | 53256082 |
Ischaemic cardiomyopathy | 22.35 | 10.38 | 21 | 63154 | 2587 | 53283304 |
Pregnancy | 22.20 | 10.38 | 5 | 63170 | 31436 | 53254455 |
Cardiac valve disease | 21.48 | 10.38 | 26 | 63149 | 4276 | 53281615 |
Renovascular hypertension | 21.31 | 10.38 | 5 | 63170 | 17 | 53285874 |
Coronary artery thrombosis | 21.12 | 10.38 | 15 | 63160 | 1244 | 53284647 |
Depressed level of consciousness | 21.06 | 10.38 | 20 | 63155 | 54408 | 53231483 |
Blood cholesterol decreased | 21.01 | 10.38 | 11 | 63164 | 525 | 53285366 |
Helicobacter infection | 20.96 | 10.38 | 10 | 63165 | 39059 | 53246832 |
Fall | 20.64 | 10.38 | 563 | 62612 | 357877 | 52928014 |
Coronary artery stenosis | 20.50 | 10.38 | 27 | 63148 | 4832 | 53281059 |
Lipids abnormal | 20.42 | 10.38 | 9 | 63166 | 292 | 53285599 |
Intentional product use issue | 20.38 | 10.38 | 34 | 63141 | 72460 | 53213431 |
Back pain | 20.37 | 10.38 | 390 | 62785 | 233857 | 53052034 |
Copper metabolism disorder | 20.19 | 10.38 | 4 | 63171 | 4 | 53285887 |
Biliary fibrosis | 20.19 | 10.38 | 4 | 63171 | 4 | 53285887 |
Peripheral artery haematoma | 19.86 | 10.38 | 6 | 63169 | 63 | 53285828 |
Acute myocardial infarction | 19.82 | 10.38 | 85 | 63090 | 33150 | 53252741 |
Pain | 19.59 | 10.38 | 539 | 62636 | 587859 | 52698032 |
Chest discomfort | 19.48 | 10.38 | 192 | 62983 | 99503 | 53186388 |
Abortion spontaneous | 19.42 | 10.38 | 16 | 63159 | 46619 | 53239272 |
Pancytopenia | 19.35 | 10.38 | 50 | 63125 | 90878 | 53195013 |
Vascular purpura | 19.31 | 10.38 | 15 | 63160 | 1426 | 53284465 |
Sleep disorder due to general medical condition, insomnia type | 19.05 | 10.38 | 3 | 63172 | 24346 | 53261545 |
Spontaneous haematoma | 19.05 | 10.38 | 12 | 63163 | 815 | 53285076 |
Sepsis | 18.96 | 10.38 | 99 | 63076 | 146330 | 53139561 |
Gastritis haemorrhagic | 18.92 | 10.38 | 15 | 63160 | 1469 | 53284422 |
Nasopharyngitis | 18.71 | 10.38 | 142 | 63033 | 192153 | 53093738 |
Obstructive pancreatitis | 18.64 | 10.38 | 8 | 63167 | 243 | 53285648 |
Blood glucose decreased | 18.52 | 10.38 | 59 | 63116 | 19957 | 53265934 |
Foetal exposure during pregnancy | 18.45 | 10.38 | 9 | 63166 | 34706 | 53251185 |
Device dislocation | 18.25 | 10.38 | 3 | 63172 | 23594 | 53262297 |
Toxic epidermal necrolysis | 18.20 | 10.38 | 3 | 63172 | 23547 | 53262344 |
Lipoprotein (a) increased | 17.99 | 10.38 | 5 | 63170 | 38 | 53285853 |
Diabetic neuropathy | 17.96 | 10.38 | 23 | 63152 | 4004 | 53281887 |
Muscle discomfort | 17.79 | 10.38 | 6 | 63169 | 92 | 53285799 |
Abnormal dreams | 17.77 | 10.38 | 39 | 63136 | 10562 | 53275329 |
Depression | 17.74 | 10.38 | 310 | 62865 | 182742 | 53103149 |
Intestinal transit time abnormal | 17.73 | 10.38 | 6 | 63169 | 93 | 53285798 |
Total cholesterol/HDL ratio decreased | 17.43 | 10.38 | 4 | 63171 | 12 | 53285879 |
Alopecia | 17.25 | 10.38 | 186 | 62989 | 234397 | 53051494 |
Carotid artery stenosis | 17.13 | 10.38 | 26 | 63149 | 5301 | 53280590 |
Therapy cessation | 16.96 | 10.38 | 72 | 63103 | 27953 | 53257938 |
Paresis | 16.93 | 10.38 | 17 | 63158 | 2272 | 53283619 |
C-reactive protein abnormal | 16.58 | 10.38 | 5 | 63170 | 25865 | 53260026 |
Respiratory disorder | 16.43 | 10.38 | 10 | 63165 | 34087 | 53251804 |
Euglycaemic diabetic ketoacidosis | 16.38 | 10.38 | 19 | 63156 | 2988 | 53282903 |
Gastric disorder | 16.37 | 10.38 | 75 | 63100 | 30090 | 53255801 |
Congenital musculoskeletal anomaly | 16.24 | 10.38 | 9 | 63166 | 482 | 53285409 |
Restless legs syndrome | 16.15 | 10.38 | 51 | 63124 | 17172 | 53268719 |
Oedema peripheral | 16.11 | 10.38 | 288 | 62887 | 170499 | 53115392 |
Low density lipoprotein decreased | 16.09 | 10.38 | 7 | 63168 | 220 | 53285671 |
Gastrooesophageal reflux disease | 16.05 | 10.38 | 159 | 63016 | 82504 | 53203387 |
Hyperphosphataemia | 15.96 | 10.38 | 16 | 63159 | 2133 | 53283758 |
Cell death | 15.82 | 10.38 | 17 | 63158 | 2458 | 53283433 |
Disease risk factor | 15.72 | 10.38 | 5 | 63170 | 63 | 53285828 |
Product use in unapproved indication | 15.63 | 10.38 | 74 | 63101 | 112215 | 53173676 |
Hepatic cyst | 15.53 | 10.38 | 24 | 63151 | 4972 | 53280919 |
Infection susceptibility increased | 15.47 | 10.38 | 17 | 63158 | 2520 | 53283371 |
Spleen congestion | 15.07 | 10.38 | 6 | 63169 | 150 | 53285741 |
Hyperparathyroidism secondary | 14.75 | 10.38 | 13 | 63162 | 1474 | 53284417 |
Chromaturia | 14.74 | 10.38 | 47 | 63128 | 15903 | 53269988 |
Stomatitis | 14.67 | 10.38 | 63 | 63112 | 98095 | 53187796 |
Anembryonic gestation | 14.58 | 10.38 | 9 | 63166 | 590 | 53285301 |
Troponin increased | 14.56 | 10.38 | 32 | 63143 | 8673 | 53277218 |
Glycosylated haemoglobin increased | 14.29 | 10.38 | 38 | 63137 | 11617 | 53274274 |
Lactic acidosis | 14.23 | 10.38 | 84 | 63091 | 37169 | 53248722 |
Psoriatic arthropathy | 14.11 | 10.38 | 22 | 63153 | 48168 | 53237723 |
Ill-defined disorder | 14.07 | 10.38 | 23 | 63152 | 49421 | 53236470 |
Platelet count decreased | 14.03 | 10.38 | 73 | 63102 | 108026 | 53177865 |
Helicobacter gastritis | 14.00 | 10.38 | 13 | 63162 | 1577 | 53284314 |
Muscle injury | 13.97 | 10.38 | 9 | 63166 | 29757 | 53256134 |
Inappropriate schedule of product discontinuation | 13.93 | 10.38 | 3 | 63172 | 6 | 53285885 |
C-reactive protein increased | 13.93 | 10.38 | 38 | 63137 | 67848 | 53218043 |
Sedation | 13.89 | 10.38 | 9 | 63166 | 29666 | 53256225 |
Gingival oedema | 13.88 | 10.38 | 5 | 63170 | 94 | 53285797 |
Condition aggravated | 13.88 | 10.38 | 258 | 62917 | 296876 | 52989015 |
Seizure | 13.87 | 10.38 | 93 | 63082 | 129416 | 53156475 |
Blood cholesterol abnormal | 13.84 | 10.38 | 16 | 63159 | 2506 | 53283385 |
Language disorder | 13.78 | 10.38 | 14 | 63161 | 1897 | 53283994 |
Complex regional pain syndrome | 13.74 | 10.38 | 15 | 63160 | 2208 | 53283683 |
Irritable bowel syndrome | 13.67 | 10.38 | 19 | 63156 | 43613 | 53242278 |
Blood creatine phosphokinase MM increased | 13.60 | 10.38 | 4 | 63171 | 38 | 53285853 |
Cataract | 13.59 | 10.38 | 103 | 63072 | 49517 | 53236374 |
Hypertension | 13.49 | 10.38 | 356 | 62819 | 225075 | 53060816 |
Pulmonary pain | 13.36 | 10.38 | 15 | 63160 | 2277 | 53283614 |
Vitamin D deficiency | 13.11 | 10.38 | 38 | 63137 | 12210 | 53273681 |
Intervertebral disc degeneration | 13.09 | 10.38 | 42 | 63133 | 14256 | 53271635 |
Necrotising myositis | 12.87 | 10.38 | 7 | 63168 | 361 | 53285530 |
Myoglobin blood increased | 12.84 | 10.38 | 12 | 63163 | 1468 | 53284423 |
Hypocholesterolaemia | 12.79 | 10.38 | 5 | 63170 | 119 | 53285772 |
Hypotrichosis | 12.75 | 10.38 | 5 | 63170 | 120 | 53285771 |
Peripheral swelling | 12.63 | 10.38 | 170 | 63005 | 205938 | 53079953 |
Malignant neoplasm progression | 12.57 | 10.38 | 43 | 63132 | 71498 | 53214393 |
Muscle atrophy | 12.49 | 10.38 | 25 | 63150 | 6349 | 53279542 |
Arteriosclerosis | 12.43 | 10.38 | 33 | 63142 | 10078 | 53275813 |
Premature baby | 12.38 | 10.38 | 4 | 63171 | 19797 | 53266094 |
Suicide attempt | 12.36 | 10.38 | 32 | 63143 | 58136 | 53227755 |
Drug dependence | 12.30 | 10.38 | 5 | 63170 | 21467 | 53264424 |
Non-high-density lipoprotein cholesterol increased | 12.23 | 10.38 | 5 | 63170 | 134 | 53285757 |
Mucosal inflammation | 12.08 | 10.38 | 20 | 63155 | 42764 | 53243127 |
Pancreatitis relapsing | 12.07 | 10.38 | 9 | 63166 | 805 | 53285086 |
Neutrophil count decreased | 12.05 | 10.38 | 25 | 63150 | 49073 | 53236818 |
Pulmonary haematoma | 12.00 | 10.38 | 4 | 63171 | 59 | 53285832 |
Hypersensitivity pneumonitis | 11.97 | 10.38 | 15 | 63160 | 2555 | 53283336 |
Pleural effusion | 11.96 | 10.38 | 59 | 63116 | 88520 | 53197371 |
Septic shock | 11.91 | 10.38 | 36 | 63139 | 62193 | 53223698 |
Impaired quality of life | 11.91 | 10.38 | 21 | 63154 | 4850 | 53281041 |
Blood pressure increased | 11.89 | 10.38 | 233 | 62942 | 140246 | 53145645 |
Ear haemorrhage | 11.86 | 10.38 | 11 | 63164 | 1333 | 53284558 |
Pneumonia aspiration | 11.71 | 10.38 | 14 | 63161 | 34287 | 53251604 |
Weight decreased | 11.57 | 10.38 | 362 | 62813 | 234586 | 53051305 |
Abdominal pain upper | 11.56 | 10.38 | 268 | 62907 | 166023 | 53119868 |
Discomfort | 11.55 | 10.38 | 66 | 63109 | 95406 | 53190485 |
Nephropathy | 11.53 | 10.38 | 22 | 63153 | 5395 | 53280496 |
Blister | 11.49 | 10.38 | 51 | 63124 | 78702 | 53207189 |
Xanthelasma | 11.37 | 10.38 | 4 | 63171 | 70 | 53285821 |
Acquired epidermolysis bullosa | 11.32 | 10.38 | 4 | 63171 | 71 | 53285820 |
Autoimmune hepatitis | 11.11 | 10.38 | 28 | 63147 | 8290 | 53277601 |
Nasal cyst | 11.07 | 10.38 | 4 | 63171 | 76 | 53285815 |
Antiphospholipid syndrome | 11.06 | 10.38 | 12 | 63163 | 1754 | 53284137 |
Purpura | 10.98 | 10.38 | 33 | 63142 | 10820 | 53275071 |
Small intestinal haemorrhage | 10.93 | 10.38 | 13 | 63162 | 2098 | 53283793 |
Renal tubular necrosis | 10.88 | 10.38 | 34 | 63141 | 11385 | 53274506 |
Cerebellar syndrome | 10.75 | 10.38 | 17 | 63158 | 3590 | 53282301 |
Peroneal nerve palsy | 10.72 | 10.38 | 19 | 63156 | 4404 | 53281487 |
Rash | 10.71 | 10.38 | 426 | 62749 | 445765 | 52840126 |
Low density lipoprotein abnormal | 10.71 | 10.38 | 5 | 63170 | 186 | 53285705 |
White blood cell count decreased | 10.69 | 10.38 | 95 | 63080 | 124380 | 53161511 |
Hyperleukocytosis | 10.68 | 10.38 | 7 | 63168 | 509 | 53285382 |
Encephalopathy | 10.59 | 10.38 | 17 | 63158 | 36791 | 53249100 |
Neoplasm progression | 10.44 | 10.38 | 12 | 63163 | 29907 | 53255984 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Myalgia | 977.62 | 10.98 | 957 | 58666 | 80273 | 32373630 |
Rhabdomyolysis | 509.79 | 10.98 | 622 | 59001 | 66643 | 32387260 |
Blood creatine phosphokinase increased | 505.74 | 10.98 | 514 | 59109 | 44962 | 32408941 |
Myopathy | 315.36 | 10.98 | 218 | 59405 | 11123 | 32442780 |
Low density lipoprotein increased | 235.47 | 10.98 | 127 | 59496 | 4119 | 32449784 |
Myocardial infarction | 132.68 | 10.98 | 518 | 59105 | 125158 | 32328745 |
Death | 118.54 | 10.98 | 337 | 59286 | 382180 | 32071723 |
Coronary artery disease | 117.90 | 10.98 | 273 | 59350 | 49433 | 32404470 |
Blood cholesterol increased | 111.80 | 10.98 | 150 | 59473 | 17607 | 32436296 |
Angina pectoris | 107.91 | 10.98 | 201 | 59422 | 31225 | 32422678 |
Muscular weakness | 106.80 | 10.98 | 320 | 59303 | 67609 | 32386294 |
Drug abuse | 98.05 | 10.98 | 15 | 59608 | 80228 | 32373675 |
Toxicity to various agents | 95.05 | 10.98 | 112 | 59511 | 177929 | 32275974 |
Low density lipoprotein decreased | 92.38 | 10.98 | 43 | 59580 | 1010 | 32452893 |
Muscle spasms | 91.77 | 10.98 | 311 | 59312 | 70107 | 32383796 |
Immune-mediated myositis | 89.80 | 10.98 | 49 | 59574 | 1626 | 32452277 |
Off label use | 83.99 | 10.98 | 285 | 59338 | 306035 | 32147868 |
High density lipoprotein decreased | 76.11 | 10.98 | 57 | 59566 | 3295 | 32450608 |
Febrile neutropenia | 74.22 | 10.98 | 66 | 59557 | 119500 | 32334403 |
Venous pressure jugular increased | 71.06 | 10.98 | 33 | 59590 | 771 | 32453132 |
Pancreatitis | 67.92 | 10.98 | 188 | 59435 | 37963 | 32415940 |
Neutropenia | 58.62 | 10.98 | 107 | 59516 | 142068 | 32311835 |
Type IIa hyperlipidaemia | 57.86 | 10.98 | 20 | 59603 | 207 | 32453696 |
Myositis | 57.53 | 10.98 | 86 | 59537 | 11149 | 32442754 |
Foetal exposure during pregnancy | 57.19 | 10.98 | 5 | 59618 | 41296 | 32412607 |
Dizziness | 56.05 | 10.98 | 609 | 59014 | 209009 | 32244894 |
Angina unstable | 55.46 | 10.98 | 89 | 59534 | 12266 | 32441637 |
Blood triglycerides increased | 54.59 | 10.98 | 97 | 59526 | 14522 | 32439381 |
Completed suicide | 53.95 | 10.98 | 54 | 59569 | 92463 | 32361440 |
Drug interaction | 51.19 | 10.98 | 618 | 59005 | 217567 | 32236336 |
Hepatic enzyme increased | 48.57 | 10.98 | 164 | 59459 | 36873 | 32417030 |
Pneumonia | 47.55 | 10.98 | 420 | 59203 | 354832 | 32099071 |
Necrotising myositis | 47.37 | 10.98 | 22 | 59601 | 514 | 32453389 |
Pancreatitis acute | 46.97 | 10.98 | 133 | 59490 | 27202 | 32426701 |
Liver function test abnormal | 45.97 | 10.98 | 146 | 59477 | 31801 | 32422102 |
Suicide attempt | 44.80 | 10.98 | 8 | 59615 | 38236 | 32415667 |
Asthenia | 43.19 | 10.98 | 639 | 58984 | 235305 | 32218598 |
Blood cholesterol decreased | 41.83 | 10.98 | 25 | 59598 | 989 | 32452914 |
Amyotrophic lateral sclerosis | 38.06 | 10.98 | 24 | 59599 | 1046 | 32452857 |
Sepsis | 38.02 | 10.98 | 156 | 59467 | 158678 | 32295225 |
Acute kidney injury | 37.82 | 10.98 | 751 | 58872 | 292717 | 32161186 |
Malignant neoplasm progression | 37.07 | 10.98 | 54 | 59569 | 78442 | 32375461 |
Pyrexia | 36.96 | 10.98 | 392 | 59231 | 319576 | 32134327 |
Intentional overdose | 36.92 | 10.98 | 15 | 59608 | 41586 | 32412317 |
Chest pain | 36.56 | 10.98 | 368 | 59255 | 123769 | 32330134 |
Dyspnoea exertional | 35.78 | 10.98 | 154 | 59469 | 38807 | 32415096 |
Acute coronary syndrome | 35.72 | 10.98 | 79 | 59544 | 13862 | 32440041 |
Product use in unapproved indication | 35.58 | 10.98 | 66 | 59557 | 87138 | 32366765 |
Chromaturia | 34.81 | 10.98 | 80 | 59543 | 14398 | 32439505 |
Coronary artery occlusion | 33.96 | 10.98 | 69 | 59554 | 11416 | 32442487 |
Pancytopenia | 33.84 | 10.98 | 73 | 59550 | 91162 | 32362741 |
Erectile dysfunction | 33.56 | 10.98 | 96 | 59527 | 19743 | 32434160 |
Septic shock | 33.03 | 10.98 | 47 | 59576 | 68942 | 32384961 |
Pain in extremity | 32.41 | 10.98 | 347 | 59276 | 118554 | 32335349 |
Erythromelalgia | 31.85 | 10.98 | 9 | 59614 | 44 | 32453859 |
Cardiac failure congestive | 30.74 | 10.98 | 263 | 59360 | 84589 | 32369314 |
Dissociation | 30.69 | 10.98 | 22 | 59601 | 1188 | 32452715 |
Nonalcoholic fatty liver disease | 30.23 | 10.98 | 14 | 59609 | 325 | 32453578 |
Cutaneous lupus erythematosus | 30.10 | 10.98 | 18 | 59605 | 713 | 32453190 |
Muscle rupture | 29.83 | 10.98 | 28 | 59595 | 2214 | 32451689 |
Muscle disorder | 29.71 | 10.98 | 29 | 59594 | 2408 | 32451495 |
Drug dependence | 29.57 | 10.98 | 4 | 59619 | 23480 | 32430423 |
Disease progression | 29.39 | 10.98 | 73 | 59550 | 86789 | 32367114 |
Alanine aminotransferase increased | 29.35 | 10.98 | 245 | 59378 | 78234 | 32375669 |
Hospitalisation | 29.20 | 10.98 | 28 | 59595 | 48943 | 32404960 |
Glycogen storage disease type V | 28.85 | 10.98 | 8 | 59615 | 36 | 32453867 |
Bone marrow failure | 28.59 | 10.98 | 10 | 59613 | 30394 | 32423509 |
Ischaemic cardiomyopathy | 28.40 | 10.98 | 46 | 59577 | 6388 | 32447515 |
Cytomegalovirus infection | 28.40 | 10.98 | 6 | 59617 | 25458 | 32428445 |
White blood cell count decreased | 28.31 | 10.98 | 80 | 59543 | 91118 | 32362785 |
Stent placement | 27.80 | 10.98 | 38 | 59585 | 4537 | 32449366 |
Treatment failure | 27.58 | 10.98 | 19 | 59604 | 39144 | 32414759 |
Overdose | 27.31 | 10.98 | 76 | 59547 | 87001 | 32366902 |
Type V hyperlipidaemia | 27.29 | 10.98 | 17 | 59606 | 725 | 32453178 |
Left ventricular dysfunction | 27.20 | 10.98 | 57 | 59566 | 9638 | 32444265 |
Leukopenia | 26.80 | 10.98 | 43 | 59580 | 60079 | 32393824 |
Aspartate aminotransferase increased | 26.79 | 10.98 | 211 | 59412 | 66218 | 32387685 |
Mucosal inflammation | 26.65 | 10.98 | 14 | 59609 | 33420 | 32420483 |
Myasthenia gravis | 26.55 | 10.98 | 33 | 59590 | 3589 | 32450314 |
Ascites | 26.36 | 10.98 | 21 | 59602 | 40170 | 32413733 |
Arthralgia | 26.30 | 10.98 | 400 | 59223 | 148048 | 32305855 |
Muscle atrophy | 26.17 | 10.98 | 47 | 59576 | 7093 | 32446810 |
Low density lipoprotein abnormal | 26.17 | 10.98 | 12 | 59611 | 272 | 32453631 |
Oedema peripheral | 26.16 | 10.98 | 322 | 59301 | 113769 | 32340134 |
Left atrial dilatation | 26.11 | 10.98 | 24 | 59599 | 1848 | 32452055 |
Cardio-respiratory arrest | 25.96 | 10.98 | 39 | 59584 | 55950 | 32397953 |
Plasma cell myeloma | 25.88 | 10.98 | 41 | 59582 | 57573 | 32396330 |
Muscle injury | 25.49 | 10.98 | 20 | 59603 | 1239 | 32452664 |
Haematocrit increased | 25.36 | 10.98 | 23 | 59600 | 1740 | 32452163 |
Multiple organ dysfunction syndrome | 24.99 | 10.98 | 57 | 59566 | 69797 | 32384106 |
Rheumatoid arthritis | 24.82 | 10.98 | 27 | 59596 | 44517 | 32409386 |
Exercise lack of | 24.33 | 10.98 | 9 | 59614 | 115 | 32453788 |
Phaeochromocytoma malignant | 24.14 | 10.98 | 8 | 59615 | 72 | 32453831 |
Allergy to animal | 23.92 | 10.98 | 11 | 59612 | 251 | 32453652 |
Infection | 23.66 | 10.98 | 78 | 59545 | 84637 | 32369266 |
Dyslipidaemia | 23.58 | 10.98 | 44 | 59579 | 6839 | 32447064 |
Exercise tolerance decreased | 23.31 | 10.98 | 35 | 59588 | 4553 | 32449350 |
Pancreatic neoplasm | 23.16 | 10.98 | 17 | 59606 | 953 | 32452950 |
Dyspnoea | 22.99 | 10.98 | 845 | 58778 | 361200 | 32092703 |
Cardiac disorder | 22.75 | 10.98 | 143 | 59480 | 41723 | 32412180 |
Toxic epidermal necrolysis | 22.66 | 10.98 | 5 | 59618 | 20588 | 32433315 |
Food aversion | 22.65 | 10.98 | 12 | 59611 | 375 | 32453528 |
Restrictive pulmonary disease | 22.19 | 10.98 | 18 | 59605 | 1170 | 32452733 |
Platelet count decreased | 21.87 | 10.98 | 122 | 59501 | 114469 | 32339434 |
Pemphigoid | 21.83 | 10.98 | 48 | 59575 | 8388 | 32445515 |
Orthostatic hypotension | 21.73 | 10.98 | 99 | 59524 | 25551 | 32428352 |
Hypercholesterolaemia | 21.35 | 10.98 | 46 | 59577 | 7928 | 32445975 |
Total cholesterol/HDL ratio increased | 21.28 | 10.98 | 9 | 59614 | 167 | 32453736 |
Mucosal dryness | 20.89 | 10.98 | 17 | 59606 | 1110 | 32452793 |
Candida infection | 20.83 | 10.98 | 3 | 59620 | 16800 | 32437103 |
Neutrophil count decreased | 20.74 | 10.98 | 34 | 59589 | 47105 | 32406798 |
Acute myocardial infarction | 20.52 | 10.98 | 172 | 59451 | 54977 | 32398926 |
Hypovolaemia | 20.19 | 10.98 | 48 | 59575 | 8829 | 32445074 |
Faeces pale | 20.16 | 10.98 | 19 | 59604 | 1510 | 32452393 |
Cardiac murmur | 19.85 | 10.98 | 42 | 59581 | 7149 | 32446754 |
Tendon rupture | 19.41 | 10.98 | 42 | 59581 | 7261 | 32446642 |
Myocardial ischaemia | 19.32 | 10.98 | 74 | 59549 | 17685 | 32436218 |
Iron binding capacity total increased | 19.30 | 10.98 | 6 | 59617 | 43 | 32453860 |
Hepatitis cholestatic | 19.28 | 10.98 | 45 | 59578 | 8180 | 32445723 |
Respiratory arrest | 19.09 | 10.98 | 15 | 59608 | 28893 | 32425010 |
Intentional product use issue | 18.99 | 10.98 | 30 | 59593 | 42181 | 32411722 |
Self esteem decreased | 18.71 | 10.98 | 12 | 59611 | 539 | 32453364 |
Laryngeal discomfort | 18.60 | 10.98 | 8 | 59615 | 155 | 32453748 |
Arteriosclerosis | 18.28 | 10.98 | 53 | 59570 | 10981 | 32442922 |
Ischaemic stroke | 18.11 | 10.98 | 72 | 59551 | 17504 | 32436399 |
Spinal stenosis | 18.02 | 10.98 | 31 | 59592 | 4523 | 32449380 |
Paraesthesia | 17.93 | 10.98 | 176 | 59447 | 58768 | 32395135 |
Respiratory failure | 17.89 | 10.98 | 119 | 59504 | 107063 | 32346840 |
Neck pain | 17.88 | 10.98 | 86 | 59537 | 22701 | 32431202 |
Atrial fibrillation | 17.86 | 10.98 | 307 | 59316 | 116397 | 32337506 |
Sedation | 17.58 | 10.98 | 6 | 59617 | 18520 | 32435383 |
Thrombocytopenia | 17.33 | 10.98 | 181 | 59442 | 148118 | 32305785 |
Aldolase increased | 17.20 | 10.98 | 6 | 59617 | 64 | 32453839 |
Tumour lysis syndrome | 17.13 | 10.98 | 3 | 59620 | 14544 | 32439359 |
Hyperlipidaemia | 17.06 | 10.98 | 62 | 59561 | 14449 | 32439454 |
Coeliac disease | 16.97 | 10.98 | 12 | 59611 | 634 | 32453269 |
Suspected suicide attempt | 16.90 | 10.98 | 7 | 59616 | 123 | 32453780 |
Blood creatine phosphokinase decreased | 16.66 | 10.98 | 11 | 59612 | 519 | 32453384 |
Lymphocyte count decreased | 16.60 | 10.98 | 9 | 59614 | 21110 | 32432793 |
Back pain | 16.58 | 10.98 | 291 | 59332 | 110762 | 32343141 |
ECG signs of myocardial ischaemia | 16.41 | 10.98 | 8 | 59615 | 209 | 32453694 |
Haemoglobin increased | 16.36 | 10.98 | 24 | 59599 | 3058 | 32450845 |
Coronary artery stenosis | 16.18 | 10.98 | 47 | 59576 | 9746 | 32444157 |
Product use issue | 15.85 | 10.98 | 47 | 59576 | 52730 | 32401173 |
Agitation | 15.77 | 10.98 | 53 | 59570 | 57183 | 32396720 |
Delirium | 15.70 | 10.98 | 36 | 59587 | 44010 | 32409893 |
Infusion related reaction | 15.67 | 10.98 | 38 | 59585 | 45561 | 32408342 |
C-reactive protein increased | 15.06 | 10.98 | 42 | 59581 | 48060 | 32405843 |
Pericardial haemorrhage | 14.91 | 10.98 | 23 | 59600 | 3063 | 32450840 |
Muscle discomfort | 14.89 | 10.98 | 5 | 59618 | 47 | 32453856 |
Polymyositis | 14.87 | 10.98 | 16 | 59607 | 1490 | 32452413 |
Transaminases abnormal | 14.87 | 10.98 | 8 | 59615 | 258 | 32453645 |
Fatigue | 14.78 | 10.98 | 785 | 58838 | 349916 | 32103987 |
Flatulence | 14.43 | 10.98 | 72 | 59551 | 19283 | 32434620 |
Stomatitis | 14.24 | 10.98 | 33 | 59590 | 40196 | 32413707 |
Seizure | 14.15 | 10.98 | 122 | 59501 | 103732 | 32350171 |
Drug withdrawal syndrome | 14.00 | 10.98 | 10 | 59613 | 20221 | 32433682 |
Lipase increased | 13.95 | 10.98 | 43 | 59580 | 9214 | 32444689 |
Pancreatic carcinoma | 13.86 | 10.98 | 40 | 59583 | 8266 | 32445637 |
International normalised ratio abnormal | 13.82 | 10.98 | 23 | 59600 | 3266 | 32450637 |
Peritonitis bacterial | 13.82 | 10.98 | 3 | 59620 | 12493 | 32441410 |
Myoglobin urine | 13.77 | 10.98 | 4 | 59619 | 22 | 32453881 |
Syncope | 13.75 | 10.98 | 237 | 59386 | 89887 | 32364016 |
Thromboangiitis obliterans | 13.47 | 10.98 | 4 | 59619 | 24 | 32453879 |
Dyspnoea at rest | 13.46 | 10.98 | 23 | 59600 | 3336 | 32450567 |
Muscle strength abnormal | 13.44 | 10.98 | 5 | 59618 | 65 | 32453838 |
Blood creatine phosphokinase | 13.37 | 10.98 | 5 | 59618 | 66 | 32453837 |
Bronchopneumopathy | 13.35 | 10.98 | 9 | 59614 | 440 | 32453463 |
Hypokalaemia | 13.22 | 10.98 | 54 | 59569 | 55040 | 32398863 |
Gait disturbance | 13.20 | 10.98 | 214 | 59409 | 80194 | 32373709 |
Pseudomonas infection | 13.12 | 10.98 | 3 | 59620 | 12053 | 32441850 |
Autoimmune hepatitis | 13.10 | 10.98 | 25 | 59598 | 3950 | 32449953 |
Inspiratory capacity abnormal | 13.10 | 10.98 | 5 | 59618 | 70 | 32453833 |
Influenza like illness | 13.10 | 10.98 | 90 | 59533 | 27050 | 32426853 |
Hepatitis E virus test positive | 13.07 | 10.98 | 4 | 59619 | 27 | 32453876 |
Tumour invasion | 13.06 | 10.98 | 8 | 59615 | 331 | 32453572 |
Status epilepticus | 13.04 | 10.98 | 3 | 59620 | 12003 | 32441900 |
Peritonitis | 13.04 | 10.98 | 13 | 59610 | 22317 | 32431586 |
Disseminated intravascular coagulation | 12.96 | 10.98 | 14 | 59609 | 23162 | 32430741 |
Lower respiratory tract infection | 12.95 | 10.98 | 21 | 59602 | 29222 | 32424681 |
Diaphragmatic disorder | 12.82 | 10.98 | 13 | 59610 | 1130 | 32452773 |
Glycosylated haemoglobin increased | 12.74 | 10.98 | 45 | 59578 | 10344 | 32443559 |
Ureteric cancer recurrent | 12.71 | 10.98 | 4 | 59619 | 30 | 32453873 |
Haemorrhagic transformation stroke | 12.67 | 10.98 | 14 | 59609 | 1344 | 32452559 |
Aortic embolus | 12.63 | 10.98 | 3 | 59620 | 6 | 32453897 |
Pleural neoplasm | 12.59 | 10.98 | 4 | 59619 | 31 | 32453872 |
Depressed level of consciousness | 12.54 | 10.98 | 36 | 59587 | 40811 | 32413092 |
Neurotoxicity | 12.48 | 10.98 | 6 | 59617 | 15064 | 32438839 |
Intentional product misuse | 12.42 | 10.98 | 30 | 59593 | 36021 | 32417882 |
Electrocardiogram abnormal | 12.39 | 10.98 | 37 | 59586 | 7793 | 32446110 |
Drug ineffective for unapproved indication | 12.37 | 10.98 | 5 | 59618 | 13907 | 32439996 |
Aspergillus infection | 12.36 | 10.98 | 3 | 59620 | 11571 | 32442332 |
Dyschromatopsia | 12.34 | 10.98 | 8 | 59615 | 366 | 32453537 |
Autoimmune myositis | 12.22 | 10.98 | 5 | 59618 | 85 | 32453818 |
Abulia | 12.14 | 10.98 | 9 | 59614 | 512 | 32453391 |
Hypercapnic coma | 12.09 | 10.98 | 6 | 59617 | 163 | 32453740 |
Neoplasm progression | 12.00 | 10.98 | 11 | 59612 | 19647 | 32434256 |
Gamma-glutamyltransferase increased | 11.98 | 10.98 | 97 | 59526 | 30685 | 32423218 |
Pulmonary embolism | 11.97 | 10.98 | 97 | 59526 | 83562 | 32370341 |
Muscle fatigue | 11.82 | 10.98 | 13 | 59610 | 1241 | 32452662 |
Chronic cutaneous lupus erythematosus | 11.79 | 10.98 | 4 | 59619 | 39 | 32453864 |
Psychotic disorder | 11.70 | 10.98 | 15 | 59608 | 23005 | 32430898 |
Vertigo | 11.41 | 10.98 | 80 | 59543 | 24203 | 32429700 |
Respiratory depression | 11.34 | 10.98 | 5 | 59618 | 13206 | 32440697 |
Blood glucose increased | 11.22 | 10.98 | 175 | 59448 | 65066 | 32388837 |
Gastric dilatation | 11.18 | 10.98 | 9 | 59614 | 579 | 32453324 |
Aggression | 11.17 | 10.98 | 36 | 59587 | 39353 | 32414550 |
Coronary artery bypass | 11.06 | 10.98 | 27 | 59596 | 5049 | 32448854 |
Erythrasma | 11.04 | 10.98 | 4 | 59619 | 48 | 32453855 |
Source | Code | Description |
---|---|---|
ATC | C10AX09 | CARDIOVASCULAR SYSTEM LIPID MODIFYING AGENTS LIPID MODIFYING AGENTS, PLAIN Other lipid modifying agents |
ATC | C10BA02 | CARDIOVASCULAR SYSTEM LIPID MODIFYING AGENTS LIPID MODIFYING AGENTS, COMBINATIONS Combinations of various lipid modifying agents |
ATC | C10BA05 | CARDIOVASCULAR SYSTEM LIPID MODIFYING AGENTS LIPID MODIFYING AGENTS, COMBINATIONS Combinations of various lipid modifying agents |
ATC | C10BA06 | CARDIOVASCULAR SYSTEM LIPID MODIFYING AGENTS LIPID MODIFYING AGENTS, COMBINATIONS Combinations of various lipid modifying agents |
ATC | C10BA10 | CARDIOVASCULAR SYSTEM LIPID MODIFYING AGENTS LIPID MODIFYING AGENTS, COMBINATIONS Combinations of various lipid modifying agents |
ATC | C10BA11 | CARDIOVASCULAR SYSTEM LIPID MODIFYING AGENTS LIPID MODIFYING AGENTS, COMBINATIONS Combinations of various lipid modifying agents |
ATC | C10BA12 | CARDIOVASCULAR SYSTEM LIPID MODIFYING AGENTS LIPID MODIFYING AGENTS, COMBINATIONS Combinations of various lipid modifying agents |
FDA PE | N0000008553 | Decreased Cholesterol Absorption |
MeSH PA | D000924 | Anticholesteremic Agents |
MeSH PA | D000963 | Antimetabolites |
MeSH PA | D000960 | Hypolipidemic Agents |
MeSH PA | D057847 | Lipid Regulating Agents |
FDA EPC | N0000175911 | Dietary Cholesterol Absorption Inhibitor |
CHEBI has role | CHEBI:35221 | antimetabolite |
CHEBI has role | CHEBI:35679 | hypolipidemic agent |
CHEBI has role | CHEBI:35821 | hypocholesteremic agent |
Disease | Relation | SNOMED_ID | DOID |
---|---|---|---|
Hypercholesterolemia | indication | 13644009 | |
Hyperlipidemia | indication | 55822004 | DOID:1168 |
Familial hypercholesterolemia - homozygous | indication | 238078005 | |
Familial hypercholesterolemia - heterozygous | indication | 238079002 | |
Sitosterolemia | indication | 238104009 | DOID:0090019 |
Mixed hyperlipidemia | indication | 267434003 | |
Alopecia areata | off-label use | 68225006 | DOID:986 |
Alcoholism | contraindication | 7200002 | |
Acute nephropathy | contraindication | 58574008 | |
Disorder of muscle | contraindication | 129565002 | DOID:423 |
Liver function tests abnormal | contraindication | 166603001 | |
Acute pancreatitis | contraindication | 197456007 | DOID:2913 |
Hemorrhagic cerebral infarction | contraindication | 230706003 | |
Disease of liver | contraindication | 235856003 | DOID:409 |
Rhabdomyolysis | contraindication | 240131006 | |
Pregnancy, function | contraindication | 289908002 | |
Surgical procedure | contraindication | 387713003 | |
Breastfeeding (mother) | contraindication | 413712001 | |
SLCO1B1 Gene Variant for OATP1B1 Transporter Affecting Hepatic Clearance | contraindication | ||
Myopathy related to SLCO1B1 Gene Variant | contraindication |
Dissociation level | Dissociation constant | Type (acidic/basic) |
---|---|---|
pKa1 | 10.48 | acidic |
Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Patent number | Patent expiration date | Patent use |
---|---|---|---|---|---|---|---|---|---|---|
180MG;10MG | NEXLIZET | ESPERION THERAPS INC | N211617 | Feb. 26, 2020 | RX | TABLET | ORAL | 10118881 | Dec. 23, 2023 | USE OF NEXLIZET AS AN ADJUNCT TO DIET AND MAXIMALLY TOLERATED STATIN THERAPY TO LOWER LDL-C IN ADULTS WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA OR ESTABLISHED ATHEROSCLEROTIC CARDIOVASCULAR DISEASE |
180MG;10MG | NEXLIZET | ESPERION THERAPS INC | N211617 | Feb. 26, 2020 | RX | TABLET | ORAL | 10941095 | Dec. 23, 2023 | USE OF NEXLIZET AS AN ADJUNCT TO DIET AND MAXIMALLY TOLERATED STATIN THERAPY TO LOWER LDL-C IN ADULTS WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA OR ESTABLISHED ATHEROSCLEROTIC CARDIOVASCULAR DISEASE |
180MG;10MG | NEXLIZET | ESPERION THERAPS INC | N211617 | Feb. 26, 2020 | RX | TABLET | ORAL | 8497301 | Dec. 23, 2023 | USE OF NEXLIZET AS AN ADJUNCT TO DIET AND MAXIMALLY TOLERATED STATIN THERAPY TO LOWER LDL-C IN ADULTS WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA OR ESTABLISHED ATHEROSCLEROTIC CARDIOVASCULAR DISEASE |
180MG;10MG | NEXLIZET | ESPERION THERAPS INC | N211617 | Feb. 26, 2020 | RX | TABLET | ORAL | 9000041 | Dec. 23, 2023 | USE OF NEXLIZET AS AN ADJUNCT TO DIET AND MAXIMALLY TOLERATED STATIN THERAPY TO LOWER LDL-C IN ADULTS WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA OR ESTABLISHED ATHEROSCLEROTIC CARDIOVASCULAR DISEASE |
180MG;10MG | NEXLIZET | ESPERION THERAPS INC | N211617 | Feb. 26, 2020 | RX | TABLET | ORAL | 9624152 | Dec. 23, 2023 | USE OF NEXLIZET AS AN ADJUNCT TO DIET AND MAXIMALLY TOLERATED STATIN THERAPY FOR INHIBITING CHOLESTEROL SYNTHESIS TO LOWER LDL-C IN ADULTS WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA OR ESTABLISHED ATHEROSCLEROTIC CARDIOVASCULAR DISEASE |
10MG | ZETIA | ORGANON | N021445 | Oct. 25, 2002 | RX | TABLET | ORAL | 7612058 | Oct. 30, 2025 | REDUCTION OF ELEVATED PLASMA STEROL AND/OR STANOL LEVELS IN A MAMMAL |
10MG | ZETIA | ORGANON | N021445 | Oct. 25, 2002 | RX | TABLET | ORAL | 7612058 | Oct. 30, 2025 | TO REDUCE ELEVATED TOTAL-C, LDL-C, APO B AND NON-HDL-C IN PATIENTS WITH PRIMARY HYPERLIPIDEMIA BY ADMINISTRATION OF EZETIMIBE ALONE OR IN COMBINATION WITH A STATIN OR WITH FENOFIBRATE |
10MG;EQ 10MG BASE | ROSZET | ALTHERA PHARMS | N213072 | March 23, 2021 | RX | TABLET | ORAL | 10376470 | May 1, 2033 | TREATMENT OF HYPERLIPIDEMIA |
10MG;EQ 10MG BASE | ROSZET | ALTHERA PHARMS | N213072 | March 23, 2021 | RX | TABLET | ORAL | 9763885 | May 1, 2033 | TREATMENT OF HYPERLIPIDEMIA |
10MG;EQ 20MG BASE | ROSZET | ALTHERA PHARMS | N213072 | March 23, 2021 | RX | TABLET | ORAL | 10376470 | May 1, 2033 | TREATMENT OF HYPERLIPIDEMIA |
10MG;EQ 20MG BASE | ROSZET | ALTHERA PHARMS | N213072 | March 23, 2021 | RX | TABLET | ORAL | 9763885 | May 1, 2033 | TREATMENT OF HYPERLIPIDEMIA |
10MG;EQ 40MG BASE | ROSZET | ALTHERA PHARMS | N213072 | March 23, 2021 | RX | TABLET | ORAL | 10376470 | May 1, 2033 | TREATMENT OF HYPERLIPIDEMIA |
10MG;EQ 40MG BASE | ROSZET | ALTHERA PHARMS | N213072 | March 23, 2021 | RX | TABLET | ORAL | 9763885 | May 1, 2033 | TREATMENT OF HYPERLIPIDEMIA |
10MG;EQ 5MG BASE | ROSZET | ALTHERA PHARMS | N213072 | March 23, 2021 | RX | TABLET | ORAL | 10376470 | May 1, 2033 | TREATMENT OF HYPERLIPIDEMIA |
10MG;EQ 5MG BASE | ROSZET | ALTHERA PHARMS | N213072 | March 23, 2021 | RX | TABLET | ORAL | 9763885 | May 1, 2033 | TREATMENT OF HYPERLIPIDEMIA |
180MG;10MG | NEXLIZET | ESPERION THERAPS INC | N211617 | Feb. 26, 2020 | RX | TABLET | ORAL | 10912751 | March 14, 2036 | A METHOD OF TREATING HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA OR ESTABLISHED ATHEROSCLEROTIC CARDIOVASCULAR DISEASE BY DECREASING THE LEVEL OF LDL-C USING A FIXED DOSE COMBINATION OF 180 MG BEMPEDOIC ACID AND 10 MG EZETIMIBE |
Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Exclusivity date | Description |
---|---|---|---|---|---|---|---|---|---|
180MG;10MG | NEXLIZET | ESPERION THERAPS INC | N211617 | Feb. 26, 2020 | RX | TABLET | ORAL | Feb. 26, 2023 | NEW PRODUCT |
180MG;10MG | NEXLIZET | ESPERION THERAPS INC | N211617 | Feb. 26, 2020 | RX | TABLET | ORAL | Feb. 21, 2025 | NEW CHEMICAL ENTITY |
Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
---|---|---|---|---|---|---|---|---|---|
Niemann-Pick C1-like protein 1 | Membrane other | ANTAGONIST | Kd | 6.66 | IUPHAR | CHEMBL | |||
Niemann-Pick C1-like protein 1 | Unclassified | Ki | 6.70 | CHEMBL |
ID | Source |
---|---|
4021366 | VUID |
N0000148785 | NUI |
D01966 | KEGG_DRUG |
4021366 | VANDF |
C1142985 | UMLSCUI |
CHEBI:49040 | CHEBI |
H56 | PDB_CHEM_ID |
CHEMBL1138 | ChEMBL_ID |
D000069438 | MESH_DESCRIPTOR_UI |
DB00973 | DRUGBANK_ID |
150311 | PUBCHEM_CID |
6816 | IUPHAR_LIGAND_ID |
8010 | INN_ID |
EOR26LQQ24 | UNII |
341248 | RXNORM |
17026 | MMSL |
229065 | MMSL |
45364 | MMSL |
d04824 | MMSL |
009817 | NDDF |
408041006 | SNOMEDCT_US |
409149001 | SNOMEDCT_US |
Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
---|---|---|---|---|---|---|---|---|
Ezetimibe | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0591-3713 | TABLET | 10 mg | ORAL | ANDA | 26 sections |
Ezetimibe | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0615-8300 | TABLET | 10 mg | ORAL | ANDA | 27 sections |
Ezetimibe | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0781-5690 | TABLET | 10 mg | ORAL | ANDA | 27 sections |
Ezetimibe | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0904-6664 | TABLET | 10 mg | ORAL | ANDA | 28 sections |
Ezetimibe | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0904-7103 | TABLET | 10 mg | ORAL | ANDA | 26 sections |
ezetimibe and simvastatin | HUMAN PRESCRIPTION DRUG LABEL | 2 | 16714-778 | TABLET | 10 mg | ORAL | ANDA | 28 sections |
ezetimibe and simvastatin | HUMAN PRESCRIPTION DRUG LABEL | 2 | 16714-779 | TABLET | 10 mg | ORAL | ANDA | 28 sections |
ezetimibe and simvastatin | HUMAN PRESCRIPTION DRUG LABEL | 2 | 16714-780 | TABLET | 10 mg | ORAL | ANDA | 28 sections |
ezetimibe and simvastatin | HUMAN PRESCRIPTION DRUG LABEL | 2 | 16714-781 | TABLET | 10 mg | ORAL | ANDA | 28 sections |
Ezetimibe | Human Prescription Drug Label | 1 | 16714-813 | TABLET | 10 mg | ORAL | ANDA | 28 sections |
EZETIMIBE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 16729-433 | TABLET | 10 mg | ORAL | ANDA | 29 sections |
VYTORIN | HUMAN PRESCRIPTION DRUG LABEL | 2 | 21695-325 | TABLET | 10 mg | ORAL | NDA | 28 sections |
VYTORIN | HUMAN PRESCRIPTION DRUG LABEL | 2 | 21695-339 | TABLET | 10 mg | ORAL | NDA | 28 sections |
Zetia | HUMAN PRESCRIPTION DRUG LABEL | 1 | 21695-778 | TABLET | 10 mg | ORAL | NDA | 29 sections |
VYTORIN | HUMAN PRESCRIPTION DRUG LABEL | 2 | 21695-827 | TABLET | 10 mg | ORAL | NDA | 28 sections |
Ezetimibe and Simvastatin | HUMAN PRESCRIPTION DRUG LABEL | 2 | 43598-742 | TABLET | 10 mg | ORAL | ANDA | 28 sections |
Ezetimibe and Simvastatin | HUMAN PRESCRIPTION DRUG LABEL | 2 | 43598-743 | TABLET | 10 mg | ORAL | ANDA | 28 sections |
Ezetimibe and Simvastatin | HUMAN PRESCRIPTION DRUG LABEL | 2 | 43598-744 | TABLET | 10 mg | ORAL | ANDA | 28 sections |
Ezetimibe and Simvastatin | HUMAN PRESCRIPTION DRUG LABEL | 2 | 43598-745 | TABLET | 10 mg | ORAL | ANDA | 28 sections |
Ezetimibe and Simvastatin | HUMAN PRESCRIPTION DRUG LABEL | 2 | 45963-565 | TABLET | 10 mg | ORAL | ANDA | 27 sections |
Ezetimibe and Simvastatin | HUMAN PRESCRIPTION DRUG LABEL | 2 | 45963-566 | TABLET | 10 mg | ORAL | ANDA | 27 sections |
Ezetimibe and Simvastatin | HUMAN PRESCRIPTION DRUG LABEL | 2 | 45963-567 | TABLET | 10 mg | ORAL | ANDA | 27 sections |
Ezetimibe and Simvastatin | HUMAN PRESCRIPTION DRUG LABEL | 2 | 45963-568 | TABLET | 10 mg | ORAL | ANDA | 27 sections |
Ezetimibe | HUMAN PRESCRIPTION DRUG LABEL | 1 | 50090-3087 | TABLET | 10 mg | ORAL | ANDA | 26 sections |
Ezetimibe | Human Prescription Drug Label | 1 | 50090-3657 | TABLET | 10 mg | ORAL | ANDA | 27 sections |
Ezetimibe and Simvastatin | HUMAN PRESCRIPTION DRUG LABEL | 2 | 50090-3984 | TABLET | 10 mg | ORAL | ANDA | 27 sections |
Ezetimibe and Simvastatin | Human Prescription Drug Label | 2 | 50090-4772 | TABLET | 10 mg | ORAL | ANDA | 27 sections |
Ezetimibe | HUMAN PRESCRIPTION DRUG LABEL | 1 | 50228-379 | TABLET | 10 mg | ORAL | ANDA | 29 sections |
Ezetimibe | HUMAN PRESCRIPTION DRUG LABEL | 1 | 50268-298 | TABLET | 10 mg | ORAL | ANDA | 26 sections |
Ezetimibe and Simvastatin | HUMAN PRESCRIPTION DRUG LABEL | 2 | 51407-190 | TABLET | 10 mg | ORAL | ANDA | 28 sections |